BLRX BioLineRx Ltd. IFRS
Pharmaceutical Preparations · Nasdaq · SEC CIK 1498403 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
TTM revenue YoY-95.9%
TTM net income YoY13.0%
TTM EPS YoY100.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin80.5%
Operating margin-871.8%
Net margin-680.2%
FCF margin-686.4%
EBITDA margin-829.8%
Returns
ROE-50.7%
ROA-20.1%
ROIC (approx.)-90.4%
Asset turnover0.03x
Leverage & solvency
Liabilities / assets42.9%
Debt / equity0.00x
Current ratio1.95x
Interest coverage-8.22x
Cash quality & payout
Operating cash flow / net income1.01x
Accruals ratio0.1%
Payout ratio—
Capex / revenue2.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY2025*2025-12-31 | FY2024*2024-12-31 | FY2023*2023-12-31 | FY2022*2022-12-31 | FY2021*2021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $1.18M | $28.94M | $4.80M | $0 | $0 |
| Cost of revenue | $230,000 | $9.26M | $3.69M | $0 | $0 |
| Gross profit | $950,000 | $19.68M | $1.11M | $0 | $0 |
| R&D expense | $8.09M | $9.15M | $12.52M | $17.63M | $19.47M |
| SG&A expense | $3.14M | $6.32M | $6.31M | $5.07M | $4.31M |
| Operating income | -$10.29M | -$20.41M | -$49.69M | -$29.16M | -$24.78M |
| Interest expense | $1.25M | $9.07M | $2.14M | $1.79M | $984,000 |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$8.03M | -$9.22M | -$60.61M | -$24.95M | -$27.05M |
| EBITDA | -$9.79M | -$19.98M | -$49.11M | -$28.54M | -$24.12M |
| EPS (basic) | 0.00 | -0.01 | -0.06 | -0.03 | -0.04 |
| EPS (diluted) | 0.00 | -0.01 | -0.06 | -0.03 | -0.04 |
| Weighted avg. shares (diluted) | 2.47B | 1.20B | 963.37M | — | — |
| Balance sheet | |||||
| Cash & equivalents | $3.25M | $10.44M | $4.25M | $10.59M | $12.99M |
| Receivables | $46,000 | $2.48M | $358,000 | $0 | — |
| Inventory | $2.15M | $3.15M | $1.95M | $0 | — |
| Current assets | $23.68M | $27.10M | $47.18M | $52.00M | $57.40M |
| PP&E, netmay include right-of-use assets (IFRS) | $160,000 | $386,000 | $473,000 | $726,000 | $952,000 |
| Intangibles | $16.37M | $10.45M | $14.85M | $21.89M | $21.70M |
| Total assets | $40.91M | $38.91M | $63.92M | $76.38M | $81.39M |
| Current liabilities | $12.12M | $15.41M | $42.78M | $10.68M | $9.72M |
| Short-term debt | $4.48M | $4.48M | $3.15M | $1.54M | $2.76M |
| Total liabilities | $17.56M | $25.45M | $50.70M | $25.54M | $13.30M |
| Shareholders' equity | $18.20M | $13.46M | $13.22M | $50.84M | $68.09M |
| Cash flow statement | |||||
| Operating cash flow | -$8.07M | -$43.87M | -$22.61M | -$26.24M | -$23.57M |
| Capital expenditure | $25,000 | $53,000 | $116,000 | $131,000 | $97,000 |
| Free cash flow | -$8.10M | -$43.93M | -$22.72M | -$26.37M | -$23.67M |
| Investing cash flow | -$8.54M | $29.37M | $1.44M | $4.01M | -$38.22M |
| Financing cash flow | $8.88M | $20.66M | $15.06M | $20.44M | $57.75M |
| Depreciation & amortization | $495,000 | $431,000 | $583,000 | $615,000 | $660,000 |
| Stock-based compensation | $396,000 | $1.14M | $2.32M | $2.25M | $1.50M |
Free plan shows the latest 5 periods; Pro shows all 11 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.